Legal & General Group
TRVI icon

Legal & General Group’s Trevi Therapeutics TRVI Stock Holding History

Legal & General Group’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Buy
79,220
+15,401
+24% +$224K ﹤0.01% 2063
2026
Q1 		$761K Sell
63,819
-17,854
-22% -$200K ﹤0.01% 2231
2025
Q4 		$1.02M Sell
81,673
-299
-0.4% -$3.46K ﹤0.01% 2209
2025
Q3 		$750K Buy
81,972
+73,526
+871% +$551K ﹤0.01% 2323
2025
Q2 		$46.2K Buy
8,446
+984
+13% +$6.12K ﹤0.01% 2729
2025
Q1 		$46.9K Buy
7,462
+920
+14% +$4.39K ﹤0.01% 2734
2024
Q4 		$27K Hold
6,542
– – ﹤0.01% 2926
2024
Q3 		$21.9K Hold
6,542
– – ﹤0.01% 3016
2024
Q2 		$19.5K Buy
6,542
+2,568
+65% +$7.13K ﹤0.01% 3026
2024
Q1 		$13.7K Hold
3,974
– – ﹤0.01% 3125
2023
Q4 		$5.33K Hold
3,974
– – ﹤0.01% 3318
2023
Q3 		$8.66K Hold
3,974
– – ﹤0.01% 3295
2023
Q2 		$9.5K Buy
+3,974
New +$10K ﹤0.01% 3325

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Legal & General Group's TRVI Position: Q2 2026 in Review

Legal & General Group increased its Trevi Therapeutics (TRVI) stake by 24% in Q2 2026, buying an estimated $224K and bringing the position to 79,220 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2063.

Legal & General Group first reported a position in TRVI in Q2 2023 and has held it in 13 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Legal & General Group held 79,220 shares of Trevi Therapeutics worth $1.48M as of Q2 2026.
  • Legal & General Group bought 15,401 Trevi Therapeutics shares in Q2 2026, an estimated $224K.
  • Trevi Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2063 holding.
  • Legal & General Group first reported a position in Trevi Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.